DBV Technologies (NasdaqCM:DBVT) Update / Briefing December 16, 2025 05:00 PM ET Company ParticipantsPharis Mohideen - Chief Medical OfficerJonathan Neely - Head of Investor RelationsDaniel Tassé - CEOKevin Trapp - Chief Commercial OfficerConference Call ParticipantsAbby Gray - AnalystKristen Kluska - AnalystJon Wolleben - AnalystYatin Suneja - AnalystSam Slutsky - AnalystSushila Hernandez - AnalystOperatorWelcome to the DBV Technologies Update conference call. All participants will be in a listen-only mode ...

Core Insights - DBV Technologies has appointed Kevin Trapp as Chief Commercial Officer to lead global commercial strategy for the Viaskin® Peanut patch [1][2] - The company plans to submit a Biologics License Application (BLA) for children aged 4-7 with peanut allergies in the first half of 2026, followed by a submission for 1-3 year-olds in the second half of the same year [1][2] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions with significant unmet medical needs [4] - The company utilizes its proprietary VIASKIN® patch technology to address food allergies through epicutaneous immunotherapy (EPIT), which aims to desensitize the immune system to allergens [4] Leadership Background - Kevin Trapp has over 30 years of experience in the biopharmaceutical industry and has been involved with DBV's commercial strategy since 2017 [2][3] - Prior to rejoining DBV, Trapp served as Managing Director at Biotech Value Advisors, advising biotechnology companies on product strategy and launch planning [2][3] Product Development - The Viaskin Peanut patch aims to provide a new treatment option for families living with food allergies, addressing an urgent medical need [3][4] - DBV Technologies is currently conducting clinical trials for the VIASKIN Peanut patch in toddlers and children with peanut allergies [4]